期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

吡格列酮对胰岛素抵抗大鼠血浆纤溶酶原激活物抑制剂水平的影响

下载PDF
导出
作者 杨青兰 王建成
机构地区 宁夏回族自治区人民医院分院
出处 《山西医药杂志（上半月）》 CAS 2009年第11期1008-1010,共3页 Shanxi Medical Journal
关键词 血浆纤溶酶原激活物抑制剂 胰岛素抵抗 吡格列酮 大鼠血浆 过氧化物体增殖物激活受体 PAI-1 抗动脉粥样硬化 PPARr
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献8

  • 1李晨钟,张素华,舒昌达,任伟.用高脂肪膳食复制胰岛素抵抗大鼠模型[J].基础医学与临床,2000,20(3):93-95. 被引量：45
  • 2李光伟 潘孝仁.检测人群胰岛素敏感性的一项新指标[J].中华内分泌代谢杂志,1998,37:390-392.
  • 3Harte AL, McTernan CL, McTernan CL, et al. Rosiglitazone inhibits PAl 1 secretion in human abdominal subcutaneous adipocytes. J Diabetes Obes Metab,2003,5(5):3022-3025.
  • 4Nordt TK, Bode C, Sobel BE. Stimulation in vivo of expression of intra abdominal adipose tissue plasminogen activator inhibitor-1 by proinsulin. Diabetologia,2001,44(9) :1121-1124.
  • 5陈隽,庞久高,毛兰,严钟德.肥胖患者体脂分布与血脂、胰岛素抵抗关系探讨[J].重庆医学,2003,32(6):734-735. 被引量：10
  • 6董砚虎,王海燕,司元国,吕文山,王军,柳林,钱荣立.血浆纤溶酶原激活物抑制物1与胰岛素抵抗的相关性研究[J].中国糖尿病杂志,2002,10(4):222-226. 被引量：9
  • 7Delporte ML. Pre and post translational negative effect of beta adrenoceptor agonist sonadiponectin secretion: in vitro and in vivo studies. Biochem J, 2002,367 : 677-685.
  • 8Aljada A,Garg R, Ghanim H, et al. Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of pioglitazone in obese patients with type 2 diabetes. J Clin Endocrinol Metab,2001,86(7):3250-3256.

二级参考文献19

  • 1李光伟,Step.,L.检测人群胰岛素敏感性的一项新指数[J].中华内科杂志,1993,32(10):656-660. 被引量：2125
  • 2[1]McCormack LJ, Nagi DK, Grant PJ, et al. Plasminogen activator inhibitor-1 genotype (4G/5G) in Pima Indians:relationship to plasminogen activator inhibitor-1 levels and features of the insulin resistance syndrome. Diabetologia,1996.1512-1518.
  • 3[2]Mojca S, Pavel U, Bernd RB, et al. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 gene:relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost,1998,79:975-979.
  • 4[3]Yumiko M, Mitsuru M, Yasuo I, et al.Genotype frequency of plasminogen activator inhibitor-1(PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels.International J Hematol,1999,69:43-47.
  • 5[4]Andreas G, Jana L, Werner H, et al.The 4G/5G genotype of the plasminogen activator inhibitor-1 gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease. Thromb Haemost,1999,82:1121-1126.
  • 6[5]Grancha S, Esrelles A, Aznar J, et al. Plasminogen activator inhibitor-1(PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease.Thromb Haemost,1999, 81:516-21.
  • 7[6]Maria TS, Antonio G, Gilvaurizio P, et al. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis. Thromb Haemost,1998,80:956-60.
  • 8[7]Michael W, Mansfield J. Environmental and genetic factors in relation to elevated circulating levels of PAI-1 in caucasian patients with type two diabetes.Thromb Haemost,1997,79:842-847
  • 9[8]Potter BJ, Kluft C, Radder JK, et al.The cardiovascular risk factor PAI-1 is related to insulin resistance. Metabolism,1993,43:945-949.
  • 10[9]Haffner SM, DAgostino R Jr, Tracy R, et al.Sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care, 1999, 22:4,562-568.

共引文献62

山西医药杂志（上半月）
2009年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部